Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Researchers develop drug to eliminate disease transmission by cough

What if there was a drug that could completely eliminate airborne disease transmission that occurs when someone coughs. Researchers at the University of Alberta believe they have found a way to achieve this.

23 Sep 2010

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.

23 Sep 2010

MIDAS researchers continue to model how H1N1 may spread

As the United States prepares for the upcoming flu season, a group of researchers supported by the National Institutes of Health continues to model how H1N1 may spread.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010

U.N. MDG summit begins; UNAIDS data shows 22 African countries see drop in new HIV infections

"Ten years after world leaders set the most ambitious goals ever to tackle global poverty, they are meeting again to try to spur action to meet the targets by the 2015 deadline - which the U.N. says will be difficult, if not impossible, in some cases," the Associated Press reports. More than 140 world leaders are scheduled to participate in the three-day U.N. Summit on the Millennium Development Goals (MDGs), which kicks off Monday.

21 Sep 2010

Flu shots, heart attacks and flu prevention guidelines

According to a new British study yearly flu shots may protect against heart attacks, and the earlier in the season a shot is given the greater the protection. Niroshan Siriwardena, a professor of primary and pre-hospital health care at the University of Lincoln said, “The risk of getting a heart attack was reduced by 19 percent for those who had a vaccination in the past year.”

21 Sep 2010

H1N1 influenza increases neurological complications in children: Study

A recent study by researchers at the University of Utah determined that the 2009 pandemic influenza A (H1N1) caused a higher rate of neurological complications in children than the seasonal flu. The most common complications observed were seizures and encephalopathy.

20 Sep 2010

Male circumcision shown to help prevent HIV transmission

According to a new study published in the Medical Journal of Australia, male circumcision can be seen as a “surgical vaccine” in the fight against heterosexual HIV transmission. The study based on spread of the virus in Africa showed that there was a reduced rate of transmission in regions where male circumcision was the norm.

19 Sep 2010

Johnson & Johnson in talks to buy Crucell

Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments:

19 Sep 2010

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

18 Sep 2010

Health premiums rise as states consider how they'll implement reforms

Overall health insurance premiums rose 7 percent in 2009, even as the number of people with health coverage fell. "Individual premium revenues rose 15 percent while group premiums, which involve mostly employers, rose nearly 3 percent, according to the report from the National Association of Insurance Commissioners, an organization whose prominence has grown following passage of the new U.S. health reform law."

18 Sep 2010

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.

18 Sep 2010

Media reporting can reduce impact of infectious disease outbreaks

At the first sign of a disease pandemic, public health officials should begin strongly communicating about the extent of the outbreak and the steps that can be taken by the public to avoid infection. That's the recommendation of two mathematical biologists who have modified the most widely used infectious disease transmission model to account for the impact of news media coverage.

17 Sep 2010

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

Resident doctors report working when sick

A new study demonstrates that young doctors often fail to heed the Biblical injunction, "physician, heal thyself." In a research letter published in the September 15, 2010, issue of JAMA, researchers report that three out of five residents surveyed came to work in the previous year while sick, possibly exposing their patients and colleagues to suboptimal performance and, in many cases, communicable disease.

15 Sep 2010

ITS commences treatment in synthetic universal influenza vaccine Phase I trial

Immune Targeting Systems (ITS) Limited, one of the leading developers of synthetic vaccines for mutating viruses, today announced the first patient has been treated in its Phase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval. Over the same period the company brought in £500,000 new investment from Esperante Ventures (UK).

15 Sep 2010

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.

15 Sep 2010

More adults washing hands in public restrooms

In the latest observational study sponsored by the American Society for Microbiology and the American Cleaning Institute- (formerly The Soap and Detergent Association), 85% of adults washed their hands in public restrooms, compared with 77% in 2007. The 85% total was actually the highest observed since these studies began in 1996. The results were announced at the Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting sponsored by the American Society for Microbiology.

14 Sep 2010

Pandemic News and Research

Further Reading

Researchers develop drug to eliminate disease transmission by cough

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

MIDAS researchers continue to model how H1N1 may spread

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Researchers to develop vaccine for plague

U.N. MDG summit begins; UNAIDS data shows 22 African countries see drop in new HIV infections

Flu shots, heart attacks and flu prevention guidelines

H1N1 influenza increases neurological complications in children: Study

Male circumcision shown to help prevent HIV transmission

Johnson & Johnson in talks to buy Crucell

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

Health premiums rise as states consider how they'll implement reforms

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

Media reporting can reduce impact of infectious disease outbreaks

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Resident doctors report working when sick

ITS commences treatment in synthetic universal influenza vaccine Phase I trial

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

More adults washing hands in public restrooms

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News